-
1Academic Journal
المؤلفون: G. G. Kаrmаzаnovsky, M. Y. Shantarevich, V. I. Stashkiv, A. Sh. Revishvili, Г. Г. Кармазановский, М. Ю. Шантаревич, В. И. Сташкив, А. Ш. Ревишвили
المصدر: Medical Visualization; Том 27, № 3 (2023); 84-93 ; Медицинская визуализация; Том 27, № 3 (2023); 84-93 ; 2408-9516 ; 1607-0763
مصطلحات موضوعية: радиомика, CT, MRI, texture analysis, radiomics, КТ, МРТ, текстурный анализ
وصف الملف: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/1372/830; Allemani C., Matsuda T., Di Carlo V. et al. CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391 (10125): 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3; Hassanipour S., Vali M., Gaffari-Fam S. et al. The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. EXCLI J. 2020; 19: 108–130. https://doi.org/10.17179/excli2019-1842; Siegel R., Naishadham D., Jemal A. Cancer statistics. 2013. CA Cancer J. Clin. 2013; 63: 11–30. https://doi.org/10.3322/caac.21166; Кармазановский Г.Г., Шантаревич М.Ю. Обзор международных клинических рекомендаций и результатов клинических исследований по диагностике гепатоцеллюлярного рака за 2014–2020 годы. Анналы хирургической гепатологии. 2021; 26 (1): 12–24. https://doi.org/10.16931/1995-5464.2021112-24.; Ломовцева К.Х. Дифференциальная диагностика образований печени солидной структуры: роль диффузионно-взвешенных изображений и гепатоспецифичных контрастных средств: Дис. . канд. мед. наук. М., 2018. 117 с.; Ломовцева К.Х., Кармазановский Г.Г. Диффузионновзвешенные изображения при очаговой патологии печени: обзор литературы. Медицинская визуализация. 2015; 6: 50–60.; Semaan S., ViettiVioli N., Lewis S. et al. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid. Eur. Radiol. 2020; 30 (2): 1020–1030. https://doi.org/10.1007/s00330-019-06458-4. PMID: 31673837; An C., Lee C.H., Byun J.H. et al. Intraindividual comparison between gadoxetate-enhanced magnetic resonance imaging and dynamic computed tomography for characterizing focal hepatic lesions: a multicenter, multireader study. Korean J. Radiol. 2019; 20 (12): 1616–1626. https://doi.org/10.3348/kjr.2019.0363; Omata M., Cheng A.L., Kokudo N. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol. Int. 2017; 11 (4): 317–370. https://doi.org/10.1007/s12072-017-9799-9. PMID: 28620797; PMCID: PMC5491694; Гайдель А.В., Зельтер, П.М., Капишников А.В., Храмов А.Г. Возможности текстурного анализа компьютерных томограмм в диагностике хронической обструктивной болезни. Компьютерная оптика. 2014; 38 (4): 843–850.; Гайдель А.В., Первушкин С.С. Исследование текстурных признаков для диагностики заболеваний костной ткани по рентгеновским изображениям. Компьютерная оптика. 2013; 37.1: 113–119.; Park H.J., Park B., Lee S.S. Radiomics and Deep Learning: Hepatic Applications. Korean J. Radiol. 2020; 21 (4): 387–401. https://doi.org/10.3348/kjr.2019.0752; Ganeshan B., Miles K.A. Quantifying tumour heterogeneity with CT. Cancer Imaging. 2013; 13 (1): 140–149. https://doi.org/10.1102/1470-7330.2013.0015. PMID: 23545171; PMCID: PMC3613789.; Liang W., Shao J., Liu W. et al. Differentiating Hepatic Epithelioid Angiomyolipoma From Hepatocellular Carcinoma and Focal Nodular Hyperplasia via Radiomics Models. Front. Oncol. 2020; 10: 564307. https://doi.org/10.3389/fonc.2020.564307; Liu X., Jiang H., Chen J. et al. Gadoxetic acid disodiumenhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis. Liver Transpl. 2017; 23 (12): 1505–1518. https://doi.org/10.1002/lt.24867; Oh J., Lee J.M., Park J. et al. Hepatocellular Carcinoma: Texture Analysis of Preoperative Computed Tomography Images Can Provide Markers of Tumor Grade and DiseaseFree Survival. Korean J. Radiol. 2019; 20 (4): 569–579. https://doi.org/10.3348/kjr.2018.0501; Wu M., Tan H., Gao F. et al. Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature. Eur. Radiol. 2019; 29 (6): 2802–2811. https://doi.org/10.1007/s00330-018-5787-2; Шантаревич М.Ю., Кармазановский Г.Г. Применение текстурного анализа КТ и МР-изображений для определения степени дифференцировки гепатоцеллюлярного рака и его дифференциальной диагностики: обзор литературы. Research'n Practical Medicine Journal. 2022; 9 (3): 129–144.; WHO Classification of Tumours 5th Edition Digestive System Tumours by WHO Classification of Tumours Editorial Board; Nioche C., Orlhac F., Boughdad S. et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018; 78 (16): 4786–4789. https://doi.org/10.1158/0008-5472.CAN-18-0125; Mao B., Zhang L., Ning P. et al. Preoperative prediction for pathological grade of hepatocellular carcinoma via machine learning-based radiomics. Eur. Radiol. 2020; 30 (12): 6924–6932. https://doi.org/10.1007/s00330-020-07056-5; Liu X., Khalvati F., Namdar K. et al. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning? Eur. Radiol. 2021; 31 (1): 244–255. https://doi.org/10.1007/s00330-020-07119-7; Meng X.P., Wang Y.C., Zhou J.Y. et al. Comparison of MRI and CT for the prediction of microvascular invasion in solitary hepatocellular carcinoma based on a nonradiomics and radiomics method: which imaging modality is better? J. Magn. Reson. Imaging. 2021; 54 (2): 526–536. https://doi.org/10.1002/jmri.27575.; Hu H.T., Shan Q.Y., Chen S.L. et al. CT-based radiomics for preoperative prediction of early recurrent hepatocellular carcinoma: technical reproducibility of acquisition and scanners. Radiol. Med. 2020; 125 (8): 697–705. https://doi.org/10.1007/s11547-020-01174-2; Shafiq-Ul-Hassan M., Zhang G.G., Latifi K. et al. Intrinsic dependencies of CT radiomic features on voxel size and number of gray levels. Medical physics. 201744 (3): 1050–1062. https://doi.org/10.1002/mp.12123; Sun R., Limkin E.J., Vakalopoulou M., et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018; 19 (9): 1180–1191. https://doi.org/10.1016/S1470-2045(18)30413-3; https://medvis.vidar.ru/jour/article/view/1372
-
2Academic Journal
المؤلفون: G. G. Kаrmаzаnovsky, K. A. Zamyatina, V. I. Stashkiv, M. Yu. Shantarevich, E. V. Kondratyev, F. M. Semenov, S. Yu. Kuznetsova, A. V. Kozlova, G. P. Plotnikov, V. A. Popov, A. V. Chupin, A. A. Gritskevich, A. M. Chililov, A. A. Pechetov, A. I. Kurochkina, V. A. Khokhlov, D. V. Kalinin, Г. Г. Кармазановский, К. А. Замятина, В. И. Сташкив, М. Ю. Шантаревич, Е. В. Кондратьев, Ф. М. Семенов, С. Ю. Кузнецова, А. В. Козлова, Г. П. Плотников, В. А. Попов, А. В. Чупин, А. А. Грицкевич, А. М. Чилилов, А. А. Печетов, А. И. Курочкина, В. А. Хохлов, Д. В. Калинин
المصدر: Medical Visualization; Том 24, № 2 (2020); 11-36 ; Медицинская визуализация; Том 24, № 2 (2020); 11-36 ; 2408-9516 ; 1607-0763
مصطلحات موضوعية: консолидация, CT, viral pneumonia, ground-glass opacity, consolidation, КТ, вирусная пневмония, “матовое стекло”
وصف الملف: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/911/622; https://medvis.vidar.ru/jour/article/view/911/623; Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Zhong N.S.; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020; 382 (18): 1708–1720. http://doi.org/10.1056/NEJMoa2002032. Epub 2020 Feb 28. PMID: 32109013; PMCID: PMC7092819.; WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19---11-march-2020; World Health Organization.Pneumonia of unknown cause – China. Accessed January 5, 2020. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-causechina/en/; Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A., Haagmans B.L., Lauber C., Leontovich A.M., Neuman B.W., Penzar D., Perlman S., Poon L.L.M., Samborskiy D.V., Sidorov I.A., Sola I., Ziebuhr J. The species severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020; 5 (4): 536–544. https://doi.org/10.1038/s41564-020-0695-z; Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J. Pediatr. 2020; 87 (4): 281–286. https://doi.org/10.1007/s12098-020-03263-6. Epub 2020 Mar 13. PMID: 32166607; PMCID: PMC7090728.; Coronavirus disease (COVID-19) Situation dashboard. World Health Organization, 24 May 2020. https://covid19.who.int; Infantino M., Damiani A., Gobbi F.L., Grossi V., Lari B., Macchia D., Casprini P., Veneziani F., Villalta D., Bizzaro N., Cappelletti P., Fabris M., Quartuccio L., Benucci M., Manfredi M. Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. Isr. Med. Assoc. J. 2020; 22 (4): 203–210. PMID: 32286019.; Zhai P., Ding Y., Wu X., Long J., Zhong Y., Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int. J. Antimicrob. Agents. 2020; 55 (5): 105955. https://doi.org/10.1016/j.ijantimicag.2020.105955. Epub 2020 Mar 28. PMID: 32234468. PMCID: PMC7138178.; Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil. Med. Res. 2020; 7 (1): 11. https://doi.org/10.1186/s40779-020-00240-0. PMID: 32169119; PMCID: PMC7068984.; Xie X., Zhong Z., Zhao W., Zheng C., Wang F., Liu J. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology. 2020 Feb 12:200343. https://doi.org/10.1148/radiol.2020200343. Epub ahead of print. PMID: 32049601.; Fang Y., Zhang H., Xie J., Lin M., Ying L., Pang P., Ji W. Sensitivity of Chest CT for COVID-19: Comparison to RTPCR. Radiology. 2020 Feb 19:200432. https://doi.org/10.1148/radiol.2020200432. Epub ahead of print. PMID: 32073353.; Ye Z., Zhang Y., Wang Y., Wang Y., Huang Z., Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur. Radiol. 2020. https://doi.org/10.1007/s00330-020-06801-0. Published: 19 March 2020; Морозов С.П., Проценко Д.Н., Сметанина С.В., Андрейченко А.Е., Амброси О.Е., Баланюк Э.А., Владзимирский А.В., Ветшева Н.Н., Гомболевский В.А., Епифанова С.В., Ледихова Н.В., Лобанов М.Н., Павлов Н.А., Панина Е.В., Полищук Н.С., Ридэн Т.В., Соколина И.А., Туравилова Е.В., Федоров С.С., Чернина В.Ю., Шулькин И.М. Лучевая диагностика коронавирусной болезни (COVID-19): организация, методология, интерпретация результатов. М.: ДЗ г. Москвы, 2020. 81 с. http://medradiology.moscow/f/luchevaya_diagnostika_koronavirusnoj_infekcii_covid-19_v2.pdf; Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020). 165 c. https://www.rosminzdrav.ru/ministry/med_covid19; Wadman M., Couzin-Frankel J., Kaiser J., Matacic C. How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes. 2020; 6: 45 P.; Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., Li W.W., Li V.W., Mentzer S.J., Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med. 2020 May 21. https://doi.org/10.1056/NEJMoa2015432. Epub ahead of print. PMID: 32437596.; Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., Wang X. Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. https://doi.org/10.1101/2020.02.19.956235. https://www.biorxiv.org/content/10.1101/2020.02.19.956235v1.article-info; Lax S.F., Skok K., Zechner P., Kessler H.H., Kaufmann N., Koelblinger C., Vander K., Bargfrieder U., Trauner M. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series. Ann. Intern. Med. 2020 May 14. https://doi.org/10.7326/M20-2566. Epub ahead of print. PMID: 32422076.; Kuba K., Imai Y., Rao Sh., Jiang Ch., Penninger J.M. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. J. Mol. Med. (Berl). 2006; 84 (10): 814–820. https://doi.org/10.1007/s00109-006-0094-9. PMID: 16988814 PMCID: PMC7079827; Yu M., Liu Y., Xu D., Zhang R., Lan L., Xu H. Prediction of the Development of Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in Patients Discharged after Treatment for COVID-19 Pneumonia. Korean J. Radiol. 2020; 21 (6): 746–755. https://doi.org/10.3348/kjr.2020.0215. PMID: 32410413. PMCID: PMC7231610.; Xu Y.H., Dong J.H., An W.M., Lv X.Y., Yin X.P., Zhang J.Z., Dong L., Ma X., Zhang H.J., Gao B.L. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J. Infect. 2020 Apr; 80 (4): 394–400. https://orcid.org/10.1016/j.jinf.2020.02.017. Epub 2020 Feb 25. PMID: 32109443. PMCID: PMC7102535.; Tian S., Xiong Y., Liu H., Niu .L, Guo J., Liao M., Xiao S.Y. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod. Pathol. 2020: 1–8. https://orcid.org/10.1038/s41379-020-0536-x. Epub ahead of print. PMID: 32291399. PMCID: PMC7156231.; Albarello F., Pianura E., Di Stefano F., Cristofaro M., Petrone A., Marchioni L., Palazzolo C., Schininà V., Nicastri E., Petrosillo N., Campioni P., Eskild P., Zumla A., Ippolito G. COVID 19 INMI Study Group. 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation. Int. J. Infect. Dis. 2020; 93: 192–197. https://orcid.org/10.1016/j.ijid.2020.02.043. Epub 2020 Feb 26. PMID: 32112966. PMCID: PMC7110436.; https://medvis.vidar.ru/jour/article/view/911
-
3Academic Journal
المؤلفون: V. I. Stashkiv, K. A. Zamyatina, M. Yu. Shantarevich, I. V. Nikitina, G. G. Kаrmаzаnovsky, A. Sh. Revishvili, В. И. Сташкив, К. А. Замятина, М. Ю. Шантаревич, И. В. Никитина, Г. Г. Кармазановский, А. Ш. Ревишвили
المصدر: Medical Visualization; Том 24, № 2 (2020); 96-104 ; Медицинская визуализация; Том 24, № 2 (2020); 96-104 ; 2408-9516 ; 1607-0763
مصطلحات موضوعية: ИЛ-6, CT, tocilizumab, IL-6, тоцилизумаб, КТ
وصف الملف: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/916/602; Fu L., Wang B., Yuan T., Chen X., Ao Y., Fitzpatrick T., Li P., Zhou Y., Lin Y.F., Duan Q., Luo G., Fan S., Lu Y., Feng A., Zhan Y., Liang B., Cai W., Zhang L., Du X., Li L., Shu Y., Zou H. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and metaanalysis. J. Infect. 2020; 80 (6): 656–665. https://doi.org/10.1016/j.jinf.2020.03.041.; WHO main website. http://www.euro.who.int/ru/healthtopics/health-emergencies/coronavirus-covid-19 (accessed March 12, 2020); Лучевая диагностика коронавирусной болезни (COVID-19): организация, методология, интерпретация результатов. Препринт № ЦДТ – 2020 – II Версия 2 (17.04.2020). Текст: электронный.; Zhai P., Ding Y., Wu X., Long J., Zhong Y., Li Y. The epidemiology, diagnosis and treatment of COVID-19 [published online ahead of print, 2020 Mar 28]. Int. J. Antimicrob. Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105955; Временные методические рекомендации профилактики, диагностики и лечения новой коронавирусной инфекции (COVID-19) Минздрава РФ. Версия 6 от 28.04.2020.; Li Y., Xia L. Coronavirus Disease 2019 (COVID-19): role of chest CT in diagnosis and management. Am. J. Roentgenol. 2020; 214 (6): 1280–1286. https://doi.org/10.2214/AJR.20.22954; https://www.rosminzdrav.ru/ministry/med_covid19 Recommendations for doctors on Covid-19 of the Ministry of Health of the Russian Federation.; Chen J. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19. 2020; 10 (Google Scholar); Li Y., Xie Z., Lin W., Cai W., Wen C. et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). [online]. Website https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v2 [accessed 12 April 2020].; Young B.E., Ong S.W.X., Kalimuddin S., Low J.G., Tan S.Y. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020; 10 [PMC free article] [PubMed] [Google Scholar]; Chen C.Y., Wang F.L., Lin C.C. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin. Toxicology. 2006; 44: 173– 175. https://doi.org/10.1080/15563650500514558; Borba M.G.S., De Almeida Val F., Sampaio V.S., Araújo Alexandre M.A., Melo G.C. et al. Chloroquine diphosphate in two different dosages as adjunctive therapy ofhospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, doubleblinded, phase IIb clinical trial (CloroCovid-19 Study) [online]. (2020). https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v2 [accessed 12 April 2020]; Chorin E., Dai M., Shulman E., Wadhwani L., Cohen R.B. et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin [online]. 2020. https://www.medrxiv.org/content/10.1101/2020.04.02.20047050v1 [accessed 12 April 2020].; Mehra M.R., Desai S.S., Ruschitzka F., Patel A.N. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 May 22: S0140-6736(20)31180-6. https://doi.org/10.1016/S0140-6736(20)31180-6. Epub ahead of print. Erratum in: Lancet. 2020 May 30: PMID: 32450107; PMCID: PMC7255293.; Ministry of Health of the Russian Federation “On the use of the drug Hydroxychloroquine for the treatment of patients with coronavirus infection” dated May 28, 2020. https://www.rosminzdrav.ru/news/2020/05/28/14067-oprimenenii-preparata-gidroksihlorohin-dlya-lecheniyapatsientov-s-koronavirusnoy-infektsiey; Chu C.M., Cheng V.C., Hung I.F.N., Wong M.M., Chan K.H. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59: 252–256. https://doi.org/10.1136/thorax.2003.012658; Ye X.T., Luo Y.L., Xia S.C., Sun Q.F., Ding J.G., Zhou Y., Chen W., Wang X.F., Zhang W.W., Du W.J., Ruan Z.W., Hong L. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur. Rev. Med. Pharmacol. Sci. 2020; 24 (6): 3390–3396. https://doi.org/10.26355/eurrev_202003_20706. PMID: 32271456.; Assessment Report For RoActemra [Internet] 1st ed. London: European Medicines Agency; 2009. [accessed 2017January3]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_ report/human/000955/WC500054888.pdf; https://www.roche.ru/content/dam/rochexx/roche-ru/roche_russia/ru_RU/Instructions/actemra-iv-2019-12-30.pdf Версия 10 МИНЗДРАВ РОССИИ ЛСР-003012/09-301219; Higuchi T., Nakanishi T., Takada K., Matsumoto M., Okada M., Horikoshi H., Suzuki K. A case of multicentric castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, Tocilizumab. J. Korean Med. Sci. 2010; 25 (9): 1364–1367. https://doi.org/10.3346/jkms.2010.25.9.1364. PMID:20808682.; FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-andtocilizumab-cytokine-release-syndrome; Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020; 368 (6490): 473–474. https://doi.org/10.1126/science.abb8925; Le R.Q., Li L., Yuan W., Shord S.S., Nie L., Habtemariam B.A., Przepiorka D., Farrell A.T., Pazdurb R. Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018; 23 (8): 943–947. https://doi.org/10.1634/theoncologist.2018-0028; Yuan J., Zou R., Zeng L. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm. Res. 2020 Mar 29: 1–8. https://doi.org/10.1007/s00011-020-01342-0; Zhang C., Wu Z., Li J.W., Zhao H., Wang G.Q. The cytokine release syndrome (CRS) of severe COVID-19 and Inter leukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents. 2020:105954. https://doi.org/10.1016/j.ijantimicag.2020.105954.; Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of 2019 novel coronavirus infection in China. Med. Rxiv. 2019;2020:2020. https://doi.org/10.1101/2020.02.06.20020974; https://www.rosminzdrav.ru/ministry/med_covid19; Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn. Interv. Imaging. 2020; 101 (5): 323–324. https://doi.org/10.1016/j.diii.2020.03.010.; Xu X., Han M., Li T., Sun W., Wang D., Fu B., Zhou Y., Zheng X., Yang Y., Li X., Zhang X., Pan A., Wei H. Effective Treatment of Severe COVID-19 Patients With Tocilizumab. Proc. Natl. Acad. Sci. USA. 2020; 117 (20): 10970–10975. https://doi.org/10.1073/pnas.2005615117; Michot J.-M., Albiges L., Chaput N., Saada V., Pommeret F., Griscelli F., Balleyguier C., Besse B., Marabelle A., Netzer F., Merad M., Robert C., Barlesi F., Gachot B., Stoclin A. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann. Oncol. 2020 Apr 2: S0923-7534(20)36387-0. https://doi.org/10.1016/j.annonc.2020.03.300; Wang L., Peng X., Wang Z.-H., Cai J., Zhou F.-C. Tocilizumab in the treatment of a critical COVID-19 patient: a case report. Eur. Rev. Med. Pharmacol. Sci. 2020; 24 (10): 5783–5787. https://doi.org/10.26355/eurrev_202005_21372; Mihai C., Dobrota R., Schröder M., Garaiman A., Jordan S., Becker M.O., Maurer B., Distler O. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann. Rheum. Dis. 2020; 79 (5): 668–669. https://doi.org/10.1136/annrheumdis-2020-217442; The first affiliated hospital of university of science and technology. The efficacy and safety of tocilizumab in the treatment of novel coronavirus pneumonia: a multi-center, randomized, double-blinded trial. 2020. https://www.chictr.org.cn/showproj.aspx?proj=49409. Accessed 22 Feb 2020.; https://medvis.vidar.ru/jour/article/view/916
-
4
المؤلفون: V. I. Stashkiv, D. V. Kalinin, G. G. Karmazanovsky
المصدر: Diagnostic radiology and radiotherapy. 12:15-22
-
5
المؤلفون: M Yu Shantarevich, G G Karmazanovsky, V I Stashkiv, A I Kurochkina, D. V. Kalinin, A B Egorkina, Kriger Ag
المصدر: Khirurgiya. Zhurnal im. N.I. Pirogova. :11
مصطلحات موضوعية: Contrast enhancement, Contrast Media, Computed tomography, Pancreatic head, Pancreaticoduodenectomy, 030218 nuclear medicine & medical imaging, Diagnosis, Differential, 03 medical and health sciences, Tumor grade, 0302 clinical medicine, medicine.artery, Humans, Medicine, Ductal adenocarcinoma, Pancreas, Retrospective Studies, medicine.diagnostic_test, business.industry, Abdominal aorta, General Medicine, medicine.disease, Magnetic Resonance Imaging, Pancreatic Neoplasms, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Adenocarcinoma, Tomography, X-Ray Computed, business, Nuclear medicine, Carcinoma, Pancreatic Ductal